Chemical chaperones prevent protein aggregation. However, the use of chemical chaperones as drugs against diseases due to protein aggregation is limited by the very high active concentrations (mm range) required to mediate their effect. One of the most common chemical chaperones is 4-phenylbutyric acid (4-PBA). Despite its unfavorable pharmacokinetic properties, 4-PBA was approved as a drug to treat ornithine cycle diseases. Here, we report that 2-isopropyl-4-phenylbutanoic acid (5) has been found to be 2–10-fold more effective than 4-PBA in several in vitro models of protein aggregation. Importantly, compound 5 reduced the secretion rate of autism-linked Arg451Cys Neuroligin3 (R451C NLGN3).
A Lipophilic 4-Phenylbutyric Acid Derivative That Prevents Aggregation and Retention of Misfolded Proteins / Azoulay-Ginsburg, S.; Trobiani, L.; Setini, A.; Favaloro, F. L.; Giorda, E.; Jacob, A.; Hauschner, H.; Levy, L.; Cestra, G.; De Jaco, A.; Gruzman, A.. - In: CHEMISTRY-A EUROPEAN JOURNAL. - ISSN 0947-6539. - 26:8(2020), pp. 1834-1845. [10.1002/chem.201904292]
A Lipophilic 4-Phenylbutyric Acid Derivative That Prevents Aggregation and Retention of Misfolded Proteins
Trobiani L.Membro del Collaboration Group
;Setini A.Membro del Collaboration Group
;Favaloro F. L.Membro del Collaboration Group
;Cestra G.Membro del Collaboration Group
;De Jaco A.
Supervision
;
2020
Abstract
Chemical chaperones prevent protein aggregation. However, the use of chemical chaperones as drugs against diseases due to protein aggregation is limited by the very high active concentrations (mm range) required to mediate their effect. One of the most common chemical chaperones is 4-phenylbutyric acid (4-PBA). Despite its unfavorable pharmacokinetic properties, 4-PBA was approved as a drug to treat ornithine cycle diseases. Here, we report that 2-isopropyl-4-phenylbutanoic acid (5) has been found to be 2–10-fold more effective than 4-PBA in several in vitro models of protein aggregation. Importantly, compound 5 reduced the secretion rate of autism-linked Arg451Cys Neuroligin3 (R451C NLGN3).File | Dimensione | Formato | |
---|---|---|---|
Azoulay-Ginsburg_Lipophilic_2019.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
1.92 MB
Formato
Adobe PDF
|
1.92 MB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.